Related Experiment Videos
Insights
This case study documents the first human syndrome of vitamin E deficiency in a child with malabsorption, presenting with neurological and muscular issues. Treatment with vitamin E supplementation led to significant clinical improvement and normalized vitamin levels.
Area of Science:
- Neurology
- Nutritional Science
- Pediatrics
Background:
- Vitamin E deficiency is known to cause neuromuscular issues in experimental models.
- A documented human syndrome resulting from vitamin E deficiency has been lacking.
Observation:
- A 7-year-old boy with congenital malabsorption presented with progressive external ophthalmoplegia, proximal muscle weakness, peripheral neuropathy, hyporeflexia, and Babinski signs.
- Neurologic examination revealed elevated creatine phosphokinase and aldolase, slowed distal sensory latencies, type II muscle fiber atrophy.
- Plasma vitamin E levels were critically low at 8 microgram per deciliter.
Findings:
- Oral administration of water-solubilized vitamin E (400 IU daily) was initiated.
- Over 16 months, plasma vitamin E levels increased to 350 microgram per deciliter.
- This was associated with decreased sarcoplasmic enzyme activities and notable clinical improvement.
Implications:
- This report establishes the first documented human syndrome of vitamin E deficiency.
- It highlights the potential for severe neurological and muscular manifestations.
- Early diagnosis and aggressive vitamin E repletion are crucial for managing this condition.
Abstract:
Although a neuromuscular syndrome has been induced experimentally by vitamin E deficiency, a human syndrome has not yet been documented. This report describes a 7-year-old boy with severe malabsorption since birth who presented with progressive external ophthalmoplegia, proximal muscle weakness, peripheral neuropathy, hyporeflexia, and bilateral Babinski signs. Abnormalities on neurologic examination included elevated creatine phosphokinase and aldolase, slowed distal sensory latencies, type II muscle fiber atrophy, and a plasma vitamin E level of 8 microgram per deciliter (normal, 550-1500 microgram per deciliter). Treatment with oral water-solubilized vitamin E (400 IU daily; greater than 50 times the normal daily intake) was begun, with repeat laboratory studies at 3-month intervals. Over a 16-month period, plasma vitamin E content gradually increased to 350 microgram per deciliter, associated with declining sarcoplasmic enzyme activities and clinical improvement.